Your browser is no longer supported. Please, upgrade your browser.
HJLI Hancock Jaffe Laboratories, Inc. daily Stock Chart
Hancock Jaffe Laboratories, Inc.
Index- P/E- EPS (ttm)-1.11 Insider Own30.00% Shs Outstand13.70M Perf Week-3.11%
Market Cap13.27M Forward P/E- EPS next Y- Insider Trans- Shs Float8.72M Perf Month-6.85%
Income-13.00M PEG- EPS next Q- Inst Own1.30% Short Float0.24% Perf Quarter-57.37%
Sales0.20M P/S66.36 EPS this Y-138.20% Inst Trans6.58% Short Ratio0.09 Perf Half Y-44.32%
Book/sh0.23 P/B4.21 EPS next Y- ROA-240.70% Target Price- Perf Year-67.16%
Cash/sh0.20 P/C4.74 EPS next 5Y- ROE-399.90% 52W Range0.87 - 3.57 Perf YTD-34.32%
Dividend- P/FCF- EPS past 5Y- ROI-318.70% 52W High-72.84% Beta-
Dividend %- Quick Ratio1.60 Sales past 5Y- Gross Margin- 52W Low11.36% ATR0.09
Employees9 Current Ratio1.60 Sales Q/Q0.60% Oper. Margin- RSI (14)34.90 Volatility5.49% 8.29%
OptionableNo Debt/Eq0.00 EPS Q/Q70.40% Profit Margin- Rel Volume0.04 Prev Close0.98
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume221.68K Price0.97
Recom- SMA20-3.58% SMA50-32.78% SMA200-45.98% Volume8,876 Change-1.14%
Jun-27-19 08:30AM  Hancock Jaffe Reports Early Positive Results For CoreoGraft Animal Feasibility Study ACCESSWIRE +6.00%
Jun-24-19 11:00AM  Primary Investigator Dr. Jorge Hernando Ulloa Reports New and Updated VenoValve Data at C3 Global Conference ACCESSWIRE -11.01%
Jun-20-19 08:31AM  Hancock Jaffe Hires Brian Roselauf as Director of Research and Development ACCESSWIRE
Jun-19-19 01:30PM  Hancock Jaffe Primary Investigator Dr. Jorge Hernando Ulloa to Present VenoValve Report at the Venous Summit at the C3 Global Conference ACCESSWIRE +6.73%
09:31AM  What Kind Of Investor Owns Most Of Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)? Simply Wall St.
Jun-13-19 08:31AM  Hancock Jaffe Successfully Completes VenoValve Implantation for First-in-Human Study ACCESSWIRE -6.09%
Jun-12-19 09:00AM  Hancock Jaffe Announces Pricing of Public Offering of Common Stock ACCESSWIRE
Jun-07-19 08:31AM  Hancock Jaffe Reports Early Positive Results from First-In-Human VenoValve Study ACCESSWIRE -8.24%
Jun-03-19 08:31AM  Hancock Jaffe Enrolls Two Additional Patients for First-in-Human VenoValve Study ACCESSWIRE
May-28-19 08:31AM  Hancock Jaffe to Present VenoValve Case Management Report at Expert Venous Management Conference on June 7, 2019 ACCESSWIRE
May-24-19 08:31AM  Hancock Jaffe Announces Retirement of Board Chairman Yury Zhivilo ACCESSWIRE
May-21-19 08:31AM  Hancock Jaffe Expands CoreoGraft Feasibility Study ACCESSWIRE
May-08-19 08:01AM  Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates Zacks
May-06-19 08:11AM  Small Drug Stocks Outlook: Near-Term Prospects Encouraging Zacks
May-01-19 08:31AM  Hancock Jaffe Announces Successful Third Implantation for CoreoGraft Study at Texas Heart Institute ACCESSWIRE +9.17%
Apr-30-19 08:31AM  Hancock Jaffe Mourns the Loss of Director Marc Robins ACCESSWIRE
Apr-11-19 08:31AM  Hancock Jaffe Successfully Completes Four VenoValve Implantations for First-in-Human Study ACCESSWIRE +6.59%
Mar-21-19 08:31AM  Hancock Jaffe Enrolls Four Additional Patients for First-in-Human VenoValve Study ACCESSWIRE
Mar-18-19 08:31AM  Hancock Jaffe Announces Successful Start to CoreoGraft Study at Texas Heart Institute ACCESSWIRE
Mar-14-19 02:30PM  These Four Healthcare Stocks Could Test March Highs ACCESSWIRE +20.11%
Mar-13-19 08:55AM  Hancock Jaffe Completes $2.7 Million Private Placement of Common Stock ACCESSWIRE +16.00%
Feb-19-19 08:31AM  Hancock Jaffe Successfully Starts First-in-Human VenoValve Study GlobeNewswire
Jan-28-19 08:00AM  Hancock Jaffe Announces Objectives for Upcoming CoreoGraft Study GlobeNewswire
Jan-15-19 08:00AM  Dr. Marc H. Glickman to Present at 6th Israeli Vascular Access Conference GlobeNewswire
Jan-09-19 08:00AM  Hancock Jaffe Announces End Points for First-in-Human VenoValve Study GlobeNewswire
Dec-17-18 08:00AM  Hancock Jaffe Receives Approval for First-in-Human VenoValve Study GlobeNewswire -7.56%
Dec-04-18 08:00AM  Hancock Jaffe Announces January CoreoGraft Study at the Texas Heart Institute GlobeNewswire
Nov-20-18 08:00AM  Hancock Jaffe Updates Status of Application to INVIMA for First-In-Human VenoValve Trial in Colombia GlobeNewswire -5.64%
Nov-13-18 09:30AM  Hancock Jaffe Appoints Chris Sarner as Vice President of Regulatory Affairs and Quality Assurance GlobeNewswire -12.50%
Oct-09-18 06:00AM  Hancock Jaffe Enters into Sponsored Research Agreement for CoreoGraft with World-Renowned Texas Heart Institute GlobeNewswire -7.24%
Oct-02-18 06:00AM  Hancock Jaffe Appoints Three New Independent Directors GlobeNewswire -11.38%
Sep-28-18 06:00AM  Hancock Jaffe Laboratories to Present at The MicroCap Conference on October 2, 2018 in New York City GlobeNewswire
Sep-26-18 03:11PM  What Investors Should Know About Hancock Jaffe Laboratories Incs (NASDAQ:HJLI) Financial Strength Simply Wall St. -6.57%
Sep-24-18 06:00AM  Hancock Jaffe Submits Application to INVIMA for First-In-Human VenoValve Trial in Colombia GlobeNewswire
Sep-20-18 09:30AM  Diamond Equity Research Initiates Coverage on Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI) with a Valuation of $6.60 Per Share GlobeNewswire +13.00%
06:00AM  Hancock Jaffe to Present at Fourth Annual Robins Equity Research Roundup Conference GlobeNewswire
Sep-17-18 06:00AM  New Study Confirms Significant Potential U.S. Market for Hancock Jaffes VenoValve® GlobeNewswire +6.90%
Sep-12-18 06:00AM  Hancock Jaffe Laboratories VenoValve Featured in Journal of Vascular Surgery Venous and Lymphatic Disorders as a Future Option for Treating Deep Vein Disease GlobeNewswire
Aug-09-18 07:00AM  Hancock Jaffe Laboratories Receives Medical Research Committee Approval for First-in-Human VenoValve Study GlobeNewswire
Jul-24-18 07:00AM  Hancock Jaffe Laboratories Receives Ethics Committee Approval for First-in-Human VenoValve Study GlobeNewswire -5.16%
Jul-13-18 06:18PM  Hancock Jaffe Appoints Bob Rankin as Chief Financial Officer GlobeNewswire
Jul-11-18 08:00AM  Hancock Jaffe Laboratories to Conduct Analysis for FDA Submission Package for Bioprosthetic Heart Valve GlobeNewswire
Jun-20-18 08:00AM  Hancock Jaffe Laboratories Selects Site for First-in-Human VenoValve Study GlobeNewswire
Jun-12-18 02:40PM  Hancock Jaffe Laboratories, Inc. Announces Full Exercise of $1,125,000 Underwriters Over Allotment GlobeNewswire -5.84%
Jun-05-18 01:19PM  Hancock Jaffe Laboratories, Inc. Announces Closing of $7.5 Million Initial Public Offering GlobeNewswire
09:47AM  Hancock Jaffe Laboratories (HJLI) Stock: A Flagship Product That Should Not Be Ignored! ACCESSWIRE
May-31-18 07:30AM  Hancock Jaffe Laboratories, Inc. Announces Pricing of Initial Public Offering GlobeNewswire
Hancock Jaffe Laboratories, Inc., a development stage company, develops and sells biological based tissue solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. The company develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat chronic venous insufficiency; the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries; and the Bioprosthetic Heart Valve, a porcine based heart valve designed to function like a native heart valve used for pediatric heart valve recipients. It also provides research, development, and contract manufacturing services. Hancock Jaffe Laboratories, Inc. was founded in 1987 and is based in Irvine, California.